TCT 2024 - TCTMD.com
2024年10月27日 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
TCTMD - tctmd.com
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
Cheaper Version of Tirzepatide for Weight Loss Now Available, …
2024年8月28日 · The manufacturer is selling single-dose vials of the drug via its online pharmacy at around $400 to $500 for a 4-week supply.
FDA Approves Varipulse Pulsed-Field Ablation System for AF
2024年11月7日 · The US Food and Drug Administration has approved the Varipulse pulsed-field ablation (PFA) system for the treatment of drug-refractory paroxysmal atrial fibrillation (AF), device manufacturer Johnson & Johnson MedTech announced today.
SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity
2024年11月16日 · CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly 2 years in patients with obesity and heart failure with preserved ejection (HFpEF), results of the SUMMIT trial show.
SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients
2024年10月23日 · An oral formulation of semaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular events than traditional therapy alone in patients with diabetes and established CVD and/or chronic kidney disease (CKD), according to top-line results from the SOUL trial.
PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for …
2024年10月29日 · WASHINGTON, DC—In PEERLESS, the first randomized controlled trial pitting two different interventional strategies against each other in pulmonary embolism (PE), patients with acute intermediate-risk PE fared better over the short term if they received large-bore mechanical thrombectomy with the FlowTriever system (Inari Medical) rather than catheter-directed thrombolysis.
Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With …
2024年12月23日 · Tirzepatide (Zepbound; Eli Lilly) is now approved for the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, the Food and Drug Administration announced late last week.
CV Health Starts to Decline Around Age 10 | tctmd.com
2024年12月23日 · Indicators of cardiovascular health first begin to worsen around the time most US children are making the transition from elementary to middle school, data from Massachusetts suggest.
GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?
2024年11月13日 · Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) has expanded dramatically in recent years, but getting patients on all four pillars remains a challenge.. Indeed, study after study after study after study affirm that most patients who are eligible to be treated with foundational GDMT are not receiving it. . Generally, most get a beta-blocker ...